Author Correction: SARS-CoV-2 receptor binding domain radio-probe: a noninvasive approach for angiotensin-converting enzyme 2 mapping in mice

Li, Dan; Ding, Jian; Liu, Te-li; Feng, Wang; Meng, Xiangxi; Liu, Song; Yang, Zhi; Zhu, Hua

doi:10.1038/s41401-021-00848-5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KM mice (female, 18-20 g) were inoculated intratracheally with 300 μ g of RBD (in 100 μ L of PBS) or 0.01 M PBS (100 μ L) and then, after anesthetization, intraperitoneally injected with 0.2 mL of 4% chloral hydrate. This method has been described previously [ 43 ]. Then, 68 Ga-Nb1159 was injected i.v.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice

Liu

Li²,

Liu

et al. 2022

Research

Self Cite

View full text Add to dashboard Cite

Due to the rapid spread of coronavirus disease 2019 (COVID-19), there is an urgent requirement for the development of additional diagnostic tools for further analysis of the disease. The isolated nanobody Nb11-59 binds to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) with high affinity to neutralize the virus and block the angiotensin-converting enzyme 2- (ACE2-) RBD interaction. Here, we introduce a novel nanobody-based radiotracer named 68Ga-Nb1159. The radiotracer retained high affinity for the RBD and showed reliable radiochemical characteristics both in vitro and in vivo. Preclinical positron emission tomography (PET) studies of 68Ga-Nb1159 in mice revealed its rapid clearance from circulation and robust uptake into the renal and urinary systems. Fortunately, 68Ga-Nb1159 could specifically reveal the distribution of the RBD in mice. This study also helped to evaluate the pharmacodynamic effects of the neutralizing nanobody. Moreover, 68Ga-Nb1159 may be a promising tool to explore the distribution of the RBD and improve the understanding of the virus. In particular, this study identified a novel molecular radioagent and established a reliable evaluation method for specifically investigating the RBD through noninvasive and visual PET technology.

show abstract

Section: Methodsmentioning

confidence: 99%